By Dr. Lyndon Haviland
August 12, 2026
TheHill.com
Last month’s vote by a Food and Drug Administration advisory panel to ease peptide accessibility restrictions has sparked debate over the safety of this unproven class of therapeutics.
To be clear, the issue isn’t whether peptides could be useful tools to promote human health. The concern is that the integrity of the FDA advisory panel’s recommendation was undermined — it appeared to be both economically and politically driven. …
Individuals with conflicts of interest were chosen to serve on the FDA panel. Was this done to help advance the personal convictions of the leading health official in the country — Health and Human Services Secretary Robert F. Kennedy, Jr.? If so, the panel’s vote flouted science in favor of profits and politics.

